4.88

3.56% -0.18

Pre-market: 5.04 0.16 +3.28%

Lexeo Therapeutics Inc (LXEO)

Overview News Price History Financials Discussions Forecast

Lexeo Therapeutics Inc stock is traded at $4.88, with a volume of 504.48K. It is down -3.56% in the last 24 hours and up +4.72% over the past month. Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Previous Close:

$5.06

Open:

$5.12

24h Volume:

504.48K

Relative Volume:

0.54

Market Cap:

$400.39M

Revenue:

$531.00K

Net Income/Loss:

$-99.96M

P/E Ratio:

-2.2264

EPS:

-2.1919

Net Cash Flow:

$-98.96M

1W Performance:

+0.83%

1M Performance:

+4.72%

6M Performance:

-22.42%

1Y Performance:

+2.09%

1-Day Range:

$4.84

$5.204

1-Week Range:

$4.82

$5.405

52-Week Range:

$3.99

$10.99

Lexeo Therapeutics Inc Stock (LXEO) Company Profile

Name

Lexeo Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(212) 547-9879

Address

345 PARK AVENUE SOUTH, NEW YORK

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

LXEO's Discussions on Twitter

Compare LXEO vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LXEO Lexeo Therapeutics Inc	4.88	415.15M	531.00K	-99.96M	-98.96M	-2.1919
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-18-25	Initiated	Raymond James	Strong Buy
Nov-20-25	Initiated	Cantor Fitzgerald	Overweight
Oct-15-25	Initiated	Guggenheim	Buy
Jul-31-25	Initiated	Oppenheimer	Outperform
Jun-13-24	Initiated	Robert W. Baird	Outperform
Jun-06-24	Initiated	H.C. Wainwright	Buy
Nov-28-23	Initiated	Chardan Capital Markets	Buy
Nov-28-23	Initiated	JP Morgan	Overweight
Nov-28-23	Initiated	Leerink Partners	Outperform
Nov-28-23	Initiated	RBC Capital Mkts	Outperform
Nov-28-23	Initiated	Stifel	Buy

View All

Lexeo Therapeutics Inc Stock (LXEO) Latest News

Aug 20, 2026

Balyasny Asset Management L.P. Expands Stake in Lexeo Therapeuti - GuruFocus

Aug 20, 2026

Aug 19, 2026

Lexeo Therapeutics (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 3,345 Shares - MarketBeat

Aug 19, 2026

Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock - MarketBeat

Aug 19, 2026

Lexeo Therapeutics CFO Louis Edward Tamayo Sells 4,117 Shares to Settle RSU Tax Liabilities - Kalkine Media

Aug 19, 2026

Lexeo Therapeutics COO Jose Manuel Otero Sells Shares to Cover RSU Tax Liability - Kalkine Media

Aug 19, 2026

Lexeo Therapeutics CEO Richard Nolan Townsend Sells 3,345 Shares to Settle RSU Tax Liabilities - Kalkine Media

Aug 19, 2026

Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes - Stock Titan

Aug 19, 2026

Lexeo (NASDAQ: LXEO) CEO sale covers RSU tax bill, keeps 374K shares - Stock Titan

Aug 19, 2026

Lexeo Therapeutics (LXEO) COO sells 1,304 shares, retains 136K stake - Stock Titan

Aug 19, 2026

Aug 18, 2026

Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 14, 2026

Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake - Stock Titan

Aug 14, 2026

Lexeo Therapeutics (LXEO): Paradigm BioCapital reports over 5% beneficial stake - Stock Titan

Aug 14, 2026

Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99% - Stock Titan

Aug 14, 2026

Aug 13, 2026

Lexeo Therapeutics (LXEO): Affinity Asset Advisors reports 8.4% beneficial stake - Stock Titan

Aug 13, 2026

Hennion & Walsh Asset Management Inc. Invests $1.24 Million in Lexeo Therapeutics, Inc. $LXEO - MarketBeat

Aug 13, 2026

Aug 12, 2026

Lexeo Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 12, 2026

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results, Hits Estimates - marketbeat.com

Aug 12, 2026

META_TITLE_QUOTE - Yahoo Finance

Aug 12, 2026

Form 8K Lexeo Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria

Aug 12, 2026

Lexeo Therapeutics advances gene therapy and gains RMAT status - TipRanks

Aug 12, 2026

LXEO: Gene therapies for rare cardiac diseases advance with strong data, pipeline, and financial runway - TradingView

Aug 12, 2026

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times

Aug 12, 2026

Lexeo Therapeutics Announces SUNRISE-FA 2 Trial Initiation for LX2006 and Receives FDA RMAT Designation for LX2020 - Quiver Quantitative

Aug 12, 2026

Lexeo Therapeutics, Inc. 2Q 2026: Net loss $25.9M, EPS $(0.30) — 10-Q Summary - TradingView

Aug 12, 2026

Lexeo Reports $25.9 Million Q2 Net Loss as SUNRISE-FA 2 Begins - Moomoo

Aug 12, 2026

Lexeo Therapeutics (LXEO) narrows loss and ends H1 2026 with $234M cash - Stock Titan

Aug 12, 2026

Dimensional Fund Advisors LP Increases Holdings in Lexeo Therapeutics, Inc. $LXEO - MarketBeat

Aug 12, 2026

Lexeo net loss narrows to $25.9 million in Q2 FY26; R&D expenses rise to $19 million - Bitget

Aug 12, 2026

Aug 11, 2026

Lexeo Therapeutics (LXEO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat

Aug 11, 2026

Aug 10, 2026

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Aug 10, 2026

Aug 07, 2026